CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 957 enrolled
Drug / intervention
ISV-403 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00347932
NCT00347932Phase 3Completed
CompareCT.gov

A Study to Evaluate the Clinical and Microbial Efficacy of 0.6% ISV-403 Compared to Vehicle in the Treatment of Bacterial Conjunctivitis.

Bausch & Lomb Incorporated·interventional·Posted Jul 4, 2006·Updated Mar 24, 2015

In Brief

A Phase 3 clinical trial evaluating ISV-403 and Vehicle for Acute Bacterial Conjunctivitis. Completed, enrolled 957 participants.

Detailed Summary

Evaluation of the clinical and microbial efficacy of 0.6% ISV-403, compared to vehicle in the treatment of bacterial conjunctivitis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Bacterial Conjunctivitis
Countries--
Collaborators--

Timeline

Phase 3CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 4, 2006
Enrollment StartJun 1, 2006
Primary CompletionNov 1, 2007
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 20.0 years ago

Interventions

ISV-403drug

Subjects with bacterial conjunctivitis were randomized to receive 0.6% ISV-403 eye drops three times a day (TID) for 5 days.

Vehicledrug

Subjects with bacterial conjunctivitis were randomized to receive vehicle eye drops three times a day (TID) for 5 days.